These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38195887)

  • 1. Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancer.
    Young Han C; Bedia JS; Yang WL; Hawley SJ; Bergan L; Hopper M; Celestino J; Guo J; Gornet TG; Soosaipillai A; Yang H; Doskocil SD; Lokshin AE; Handy BC; Diamandis EP; Moore RG; Lu KH; Lu Z; Anderson KS; Drescher CW; Skates SJ; Bast RC
    Br J Cancer; 2024 Mar; 130(5):861-868. PubMed ID: 38195887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human epididymis protein 4 antigen-autoantibody complexes complement cancer antigen 125 for detecting early-stage ovarian cancer.
    Yang WL; Lu Z; Guo J; Fellman BM; Ning J; Lu KH; Menon U; Kobayashi M; Hanash SM; Celestino J; Skates SJ; Bast RC
    Cancer; 2020 Feb; 126(4):725-736. PubMed ID: 31714597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer.
    Guo J; Yang WL; Pak D; Celestino J; Lu KH; Ning J; Lokshin AE; Cheng Z; Lu Z; Bast RC
    Cancers (Basel); 2019 Apr; 11(5):. PubMed ID: 31035430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
    Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
    PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using a panel of multiple tumor-associated antigens to enhance the autoantibody detection in the immunodiagnosis of ovarian cancer.
    Wang P; Qin J; Ye H; Li L; Wang X; Zhang J
    J Cell Biochem; 2019 Mar; 120(3):3091-3100. PubMed ID: 30484895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
    Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
    Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer.
    Leung F; Bernardini MQ; Brown MD; Zheng Y; Molina R; Bast RC; Davis G; Serra S; Diamandis EP; Kulasingam V
    Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1333-40. PubMed ID: 27448593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
    Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
    Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.
    Anderson KS; Wong J; Vitonis A; Crum CP; Sluss PM; Labaer J; Cramer D
    Cancer Epidemiol Biomarkers Prev; 2010 Mar; 19(3):859-68. PubMed ID: 20200435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort.
    Fortner RT; Schock H; Le Cornet C; Hüsing A; Vitonis AF; Johnson TS; Fichorova RN; Fashemi T; Yamamoto HS; Tjønneland A; Hansen L; Overvad K; Boutron-Ruault MC; Kvaskoff M; Severi G; Boeing H; Trichopoulou A; Papatesta EM; La Vecchia C; Palli D; Sieri S; Tumino R; Sacerdote C; Mattiello A; Onland-Moret NC; Peeters PH; Bueno-de-Mesquita HBA; Weiderpass E; Quirós JR; Duell EJ; Sánchez MJ; Navarro C; Ardanaz E; Larrañaga N; Nodin B; Jirström K; Idahl A; Lundin E; Khaw KT; Travis RC; Gunter M; Johansson M; Dossus L; Merritt MA; Riboli E; Terry KL; Cramer DW; Kaaks R
    Int J Cancer; 2018 Apr; 142(7):1355-1360. PubMed ID: 29159934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer.
    Clarke CH; Yip C; Badgwell D; Fung ET; Coombes KR; Zhang Z; Lu KH; Bast RC
    Gynecol Oncol; 2011 Sep; 122(3):548-53. PubMed ID: 21708402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
    Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
    Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Value of Serum HE4, CA125, CA72-4, and ROMA Index for Diagnosis of Ovarian Cancer and Prediction of Postoperative Recurrence.
    Wang Q; Wu Y; Zhang H; Yang K; Tong Y; Chen L; Zhou Q; Guan S
    Clin Lab; 2019 Apr; 65(4):. PubMed ID: 30969083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
    Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN
    Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.
    Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J
    Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.
    Suri A; Perumal V; Ammalli P; Suryan V; Bansal SK
    Sci Rep; 2021 Aug; 11(1):17308. PubMed ID: 34453074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses.
    Fawzy A; Mohamed MR; Ali MA; Abd El-Magied MH; Helal AM
    Asian Pac J Cancer Prev; 2016; 17(1):323-33. PubMed ID: 26838232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a multi-marker model combining HE4, CA125, progesterone, and estradiol for distinguishing benign from malignant pelvic masses in postmenopausal women.
    Zhang P; Wang C; Cheng L; Zhang P; Guo L; Liu W; Zhang Z; Huang Y; Ou Q; Wen X; Tian Y
    Tumour Biol; 2016 Feb; 37(2):2183-91. PubMed ID: 26349751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
    Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
    Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.
    Han C; Bellone S; Siegel ER; Altwerger G; Menderes G; Bonazzoli E; Egawa-Takata T; Pettinella F; Bianchi A; Riccio F; Zammataro L; Yadav G; Marto JA; Penet MF; Levine DA; Drapkin R; Patel A; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2018 Jun; 149(3):585-591. PubMed ID: 29572027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.